STOCK TITAN

CANTA Stock News

CANTA NASDAQ
Rhea-AI Summary

Cantargia (STO:CANTA) presented positive results from two clinical trials of nadunolimab combination therapy at the ESMO Congress 2024. The trials, involving 55 patients primarily with lung cancer and head and neck cancer, showed encouraging median survival times in patients previously treated with immunotherapy. Key findings include:

1. CANFOUR trial (40 NSCLC patients): Stronger efficacy in 2nd line patients, especially non-squamous (ORR 91%, OS 26.7 months).

2. CIRIFOUR trial (15 heavily pretreated patients): Median survival of 19.7 months and disease control rate of 60%.

The data suggest nadunolimab's potential in addressing unmet medical needs, particularly in patients who have progressed on checkpoint inhibitors like pembrolizumab.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none